Expired
Lead Plaintiff Deadline
Sep 24, 2024
Choose your preferred way to stay informed of new case launches and settlement deadlines
During the class period, Defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, the investing public learned that the drug was significantly more dangerous than defendants had previously represented. Following this news, MGNX’s stock declined 77.4% due to a drop of $11.36/share.
In order to be eligible to join the MGNX class action lawsuit, you must have incurred a loss on shares of MacroGenics purchased during the class period listed above.
If you suffered a loss in MacroGenics during the relevant time frame or pursuant to the relevant offering(s), you have until September 24, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP
